Ticagrelor Alone, Without Aspirin, Shows Benefit in Patients With Diabetes

Patients with diabetes who stopped taking aspirin three months after the insertion of a coronary stent and then took the anti-platelet medication ticagrelor alone for a year had fewer episodes of bleeding and no increase in heart attacks, stroke or other adverse events caused by blockages in the arteries, compared with patients who took both aspirin and ticagrelor for a year. The research was presented at the American College of Cardiology’s Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC).

“In patients with diabetes, treatment with ticagrelor alone significantly reduced clinically relevant bleeding compared with ticagrelor plus aspirin, without increasing the risk for additional heart attacks, strokes or death,” said Dominick J. Angiolillo, MD, Ph.D., professor of medicine at the University of Florida College of Medicine in Jacksonville, Florida and first author of the study.

Learn more about Ticagrelor Alone, Without Aspirin, Shows Benefit in Patients With Diabetes.